A trial planning to use the gene-editing tool CRISPR on sickle cell patients has been put on hold due to unspecified questions from US regulators. Background: CRISPR Therapeutics, which is developing the therapy, sought approval from the US Food and Drug Administration in April to begin the study.
As a teenager, Keoni Gandall already was operating a cutting-edge research laboratory in his bedroom in Huntington Beach, California. While his friends were buying computer games, he acquired more than a dozen pieces of equipment - a transilluminator, a centrifuge, two thermocyclers - in pursuit of a hobby that once was the province of PhDs in institutional labs.
Typically, if you want to understand the foundation of something, building from the ground up sounds like a sensible approach. However, researchers in Dr. Ni's group at Harvard have taken this idea a step further by building molecules one atom at a time.
Google is drawing up a set of guidelines that will steer its involvement in developing AI tools for the military, according to a report from The New York Times . What exactly these guidelines will stipulate isn't clear, but Google says they will include a ban on the use of artificial intelligence in weaponry.
General Motors Co (GM.N) said on Thursday that Japan's SoftBank Group Corp (9984.T) will invest $2.25 billion through its Vision Fund in GM Cruise Holdings LLC, the carmaker's autonomous vehicle technology.
Kevin Esvelt wants me to know that if I fuck up this article, 25,000 children could end up dead. Esvelt is a biologist at MIT and the first person to formulate a technology known as a CRISPR gene drive, a gene editing application that represents humanity's single best chance to eradicate malaria.
After 35 years of mediocre depression drugs, pharmaceutical companies are jazzed about several new drugs inspired by the club drug ketamine. Allergan, the multinational drugmaker known for Botox, recently dove into research on an injectable depression drug. Now they're going after an oral pill.
Author: Jules Kortenhorst, CEO, Rocky Mountain Institute and Mark Dyson,Principal, Rocky Mountain Institute Around the world, an emerging "rush to gas" - a glut of investment in new natural gas-fired power plants and associated delivery infrastructure - threatens to result in significant stranded assets.
From whispering sweet nothings to hoping for sweet dreams, sugariness and pleasure have long been bound together. Now scientists studying the brains of mice have revealed why, unpicking the pathways in the brain which result in sweet foods being perceived as nice and bitter foods as nasty.
Buzzwords like "digital nomad," or "remote worker," are indicative of something bigger. Currently, freelancers are estimated to account for 34% of the workforce. By 2020, that number is set to reach 43%. Freelancing and gig economy work is often painted as the job of last resort, but people are voting with their feet: freelancing is growing rapidly while 6.6 million traditional jobs remain unfilled, an all-time high.
The autonomous cars on our roads, the automatic pilots flying our planes and the customer service software that measures our purchasing intent are all real-world examples of how rapidly AI's capabilities are expanding and touching more aspects of our lives.
CHAMPAIGN, Ill. - University of Illinois engineers built a 3-D printer that offers a sweet solution to making detailed structures that commercial 3-D printers can't: Rather than a layer-upon-layer solid shell, it produces a delicate network of thin ribbons of hardened isomalt, the type of sugar alcohol used to make throat lozenges.
Desert to Power project aims to expand solar power across the Sahel region, where electricity access remains critically low A quarter of a billion Africans could be provided with solar power from the desert, claim organisations behind a new partnership in the Sahel region.
Scientists in Japan now have permission to treat people who have heart disease with cells produced by a revolutionary reprogramming technique. The study is only the second clinical application of induced pluripotent stem (iPS) cells. These are created by inducing the cells of body tissues such as skin and blood to revert to an embryonic-like state, from which they can develop into other cell types.